HCPCS code J7328: Gelsyn-3 billing, reimbursement and coverage guide

Key Takeaways

HCPCS code J7328 describes Hyaluronan or derivative, Gelsyn-3, for intra-articular injection, per dose, billed under Medicare Part B as a physician-administered drug.

J7328 is billed per injection (not per series), so a standard 3-injection Gelsyn-3 course requires three separate claims, each with one unit.

Medicare requires documented evidence of prior conservative treatment failure before covering viscosupplementation, and the National Drug Code (NDC) must appear on every Part B claim.

Pabau’s claims management software supports accurate HCPCS code submission, NDC reporting, and modifier tracking to reduce J7328 denials.

HCPCS code J7328 is the Level II code for Hyaluronan or derivative, Gelsyn-3, for intra-articular injection, per dose. Gelsyn-3 is a hyaluronic acid (HA) viscosupplement manufactured by Bioventus and administered as a series of intra-articular knee injections for the symptomatic treatment of osteoarthritis (OA).

The “per dose” unit is the most important detail for billing teams. Gelsyn-3 is approved as a 3-injection series, but each injection generates a separate claim. Billers who submit one claim for the full series rather than three individual claims will be underpaid or denied.

When to use HCPCS code J7328: Clinical indications

J7328 applies specifically when the physician administers Gelsyn-3 intra-articularly for knee osteoarthritis. Practices treating OA patients in an orthopedic, rheumatology, or sports medicine practice environment are the primary billers for this code.

The standard clinical scenario that supports J7328 billing:

• Confirmed diagnosis of knee osteoarthritis (primary ICD-10 codes in the M17 series)
• Patient has completed a course of conservative treatment without adequate relief (physical therapy, NSAIDs, corticosteroid injections, or a combination, depending on payer policy)
• Physician determines Gelsyn-3 viscosupplementation is clinically appropriate
• Injection is administered intra-articularly in the physician office setting
• Each injection in the 3-dose series is billed individually as 1 unit of J7328

J7328 covers the drug itself. The administration is billed separately using the appropriate injection administration code (typically CPT 20610 for aspiration or injection of a major joint). Both codes appear on the same claim for a complete encounter.

J7328 reimbursement rates and fee schedule

Medicare reimburses J7328 under the Medicare Part B drug payment methodology. For physician-administered drugs, the standard rate is Average Sales Price (ASP) plus 6%, calculated at the time of claim processing. Because ASP updates quarterly and the Physician Fee Schedule updates annually, the reimbursement rate for J7328 changes throughout the year.

Practices should pull current rates directly from the CMS Physician Fee Schedule lookup tool or verify with their Medicare Administrative Contractor (MAC) before billing. Rates also vary by geographic practice cost index (GPCI), meaning a practice in San Francisco will receive a higher reimbursement than one in rural Mississippi for the same code.

Commercial payers set their own rates and may reimburse above or below Medicare. Verify each payer’s fee schedule or contracted rate before administering Gelsyn-3 under a buy-and-bill arrangement.

Medicare and insurance coverage for J7328

Medicare Part B covers viscosupplementation with Gelsyn-3 (HCPCS code J7328) under Local Coverage Determinations (LCDs) issued by individual MACs. The two primary CMS billing and coding articles governing hyaluronan injections are article A52420 and article A56157. Before billing, practices should confirm which LCD is active in their MAC jurisdiction, as coverage criteria vary regionally.

Routine Medicare coverage criteria for J7328 include:

• Confirmed diagnosis of primary or secondary knee osteoarthritis (not hip, shoulder, or other joints)
• Documented failure of at least one form of conservative treatment (physical therapy, analgesics, NSAIDs, or corticosteroid injections), with the duration and specifics varying by MAC policy
• Injection administered in a Medicare-participating physician office or outpatient setting
• NDC reported on the claim (11-digit format, mandatory for all Part B drug claims)
• Claim submitted with appropriate ICD-10-CM diagnosis code from the covered list

Thorough insurance eligibility verification before each injection in the series is essential. Coverage limits on total injections per knee per year vary by payer, and some commercial plans exclude viscosupplementation entirely. Checking eligibility ahead of the second and third injections prevents mid-series claim rejections.

ICD-10 diagnosis codes required with J7328

Every J7328 claim requires a covered ICD-10-CM diagnosis code for the knee osteoarthritis condition being treated. The M17 series (osteoarthritis of the knee) represents the primary covered codes under most Medicare LCDs. Submitting a J7328 claim with an ICD-10 code outside the covered list triggers an automatic denial.

Payer-specific covered code lists may be broader or narrower than the above. Always verify the current covered diagnosis code list in your MAC’s active LCD. Some payers also cover post-traumatic or unspecified osteoarthritis codes; others restrict coverage to primary OA only.

Modifiers used with J7328

Modifiers on a J7328 claim communicate laterality and service circumstances to the payer. Using the wrong modifier, or omitting one when required, results in denial or incorrect payment. The most commonly used modifiers are shown below. Practices should verify modifier requirements with their specific MAC, as requirements may differ by jurisdiction.

For bilateral knee injections in a single session, some MACs require billing two separate line items (J7328 LT and J7328 RT) rather than modifier 50. Confirm your MAC’s specific policy to avoid bilateral claim edits.

Buy-and-bill billing for J7328

Gelsyn-3 is typically administered under the buy-and-bill model: the practice purchases the drug from a supplier, administers it in-office, and then bills the payer for the drug and administration separately. This model carries more financial and administrative risk than a pharmacy-dispensed drug because the practice absorbs the acquisition cost upfront.

Sound revenue cycle management for buy-and-bill drugs requires tracking acquisition cost, dose administration, claim submission timelines, and reimbursement reconciliation. The step-by-step workflow:

1. Acquire Gelsyn-3: Purchase the product from an authorized distributor. Track the National Drug Code (NDC) from the specific lot received, as Medicare requires the exact 11-digit NDC on the claim.
2. Confirm patient eligibility and coverage: Verify Medicare or commercial coverage, conservative treatment documentation, and any prior authorization requirements before the first injection.
3. Administer the injection: Document the injection site (laterality), dose administered, drug NDC and lot number, and the administering provider in the clinical note.
4. Submit the claim: Bill J7328 (1 unit per injection) alongside CPT 20610 for the administration. Include the NDC in the correct format (11-digit, qualifier N4) in the appropriate claim field. Attach relevant modifiers (LT or RT). Use Pabau’s claims management software to manage HCPCS code submission and modifier attachment across each injection in the series.
5. Reconcile reimbursement: Match the remittance advice payment to the acquisition cost. Any gap between ASP+6% and acquisition cost represents a potential margin risk that practices should monitor per lot.

NDC reporting errors are the single most common technical denial for buy-and-bill drug claims. The CMS HCPCS Level II guidelines require the NDC to be submitted on all Part B drug claims using the N4 qualifier with the 11-digit code in NNNNNNNNNN format. A missing or incorrectly formatted NDC results in a claim rejection before it reaches the payer’s adjudication system.

Manage J7328 claims with less admin

Pabau’s claims management software helps orthopedic and rheumatology practices track HCPCS drug codes, modifiers, and NDC requirements across every injection in the buy-and-bill cycle. Fewer errors. Faster reimbursement.

Book a demo

Documentation requirements for J7328

Medicare auditors reviewing viscosupplement claims look for a specific set of clinical record elements. Claims that pass adjudication but fail post-payment audit result in recoupment, which is more disruptive than a front-end denial. Building complete superbill documentation habits for every J7328 encounter reduces audit exposure.

Required documentation elements for J7328 medical necessity support:

• Knee OA diagnosis: Objective findings confirming osteoarthritis, such as imaging reports (X-ray or MRI) showing joint space narrowing, osteophytes, or cartilage loss
• Conservative treatment trial: Dates, types, and duration of prior treatments attempted (physical therapy sessions, NSAID courses, steroid injections) with documented inadequate response
• Clinical indication for viscosupplementation: Physician’s rationale for choosing Gelsyn-3, referencing the patient’s functional limitations and conservative treatment failure
• Injection details: Date of service, laterality (left vs. right knee), drug name and NDC, lot number, dose administered, and site of injection
• Administration note: Provider who administered the injection, method (intra-articular), and any joint aspiration performed at the same visit
• Series tracking: Record of which injection in the 3-dose series is being administered (injection 1, 2, or 3)

Good medical billing compliance practice is to store these documentation elements in a structured clinical note that maps directly to the claim fields. A note that simply says “knee injection given” without the elements above will not survive an audit.

Prior authorization requirements for J7328

Traditional Medicare (fee-for-service) does not require prior authorization for J7328 viscosupplementation under most MAC jurisdictions. However, Medicare Advantage plans, Medicaid managed care organizations, and commercial payers may require prior authorization before the first injection, and sometimes before each subsequent injection in the series.

Common prior authorization requirements across commercial payers:

• Confirmed knee OA diagnosis with imaging evidence
• Documented conservative treatment failure, typically 3-6 months of conservative therapy, though requirements vary by payer
• Specific product authorization (some plans will approve one viscosupplement brand but not another, so approval for a different product does not extend to Gelsyn-3)
• Frequency limitations, such as one series per knee per 6-12 months

Billing for J7328 without required prior authorization results in denial regardless of medical necessity. Always verify each payer’s current policy before ordering the drug. Because authorization requirements change with plan year renewals, a workflow that was approved in prior years may now require pre-authorization.

Common billing errors and denial reasons for HCPCS code J7328

J7328 denials concentrate in a few predictable categories. Understanding them upfront prevents the revenue leakage that comes from billing patterns that trigger systematic edits. Proactive denial management strategies for viscosupplement claims should focus on these root causes:

Submitting a clean claim for J7328 means every field is correct before the claim leaves the practice. A systematic pre-submission checklist covering ICD-10 code validity, NDC format, modifier presence, and prior authorization status eliminates the majority of the denial categories above.

Related HCPCS viscosupplementation codes

J7328 is one of several HCPCS J-codes covering hyaluronan-based viscosupplements. Each code maps to a specific branded product and injection series. Billing the correct code for the actual product administered is a medical necessity and compliance requirement. The AAPC HCPCS Level II code lookup provides current descriptors for all J7xxx viscosupplement codes.

Billing the wrong viscosupplement code for the product actually administered constitutes a coding error and potentially a compliance violation. Confirm the product dispensed against the J-code on the claim before submission. For practices managing multiple viscosupplement products, reviewing medical billing software that enforces product-to-code matching reduces this risk.

Conclusion

Viscosupplement billing fails most often not because of coverage exclusions but because of process gaps: a missing NDC, an undocumented conservative therapy trial, or a laterality modifier that was never added. Each of these is preventable with the right workflow.

Pabau’s claims management software helps orthopedic and rheumatology practices build those workflows into their billing cycle, from eligibility checks before the first injection through NDC entry, modifier selection, and remittance reconciliation for all three doses in the Gelsyn-3 series. For practices looking to reduce J7328 denials and speed up reimbursement, book a demo to see how Pabau handles buy-and-bill drug claims end to end.

Continue your research

Need to understand how HCPCS drug claims move through the billing cycle? What is medical billing walks through the full process from patient encounter to payment posting.

Want to reduce claim rejections before they reach adjudication? Clean claim submission outlines the field-by-field requirements that prevent front-end rejections on drug claims.

Building a strategy to recover denied viscosupplement claims? Denial management strategies covers root-cause analysis and appeal workflows for physician-administered drug denials.

Frequently Asked Questions